Nutex Health (NUTX) Research & Development (2019 - 2022)

Nutex Health has disclosed Research & Development across 4 years of filings, most recently posting $73750.0 for Q1 2022.

• Research & Development for Q1 2022 came in at $73750.0, down 3.87% year-over-year; the trailing twelve-month figure through Mar 2022 was $282910.0 (down 45.5% YoY), and the FY2021 annual result was $285880.0, down 48.7% from the prior year.
• Research & Development came in at $73750.0 for Q1 2022 at Nutex Health, down from $77265.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $314255.0 in Q2 2020 to a low of $54296.0 in Q4 2020.
• The 4-year median for Research & Development is $77265.0 (2021), against an average of $129614.6.
• Peak annual rise in Research & Development reached 42.3% in 2021, while the deepest fall reached 81.03% in 2021.
• Nutex Health's Research & Development stood at $196632.0 in 2019, then tumbled by 72.39% to $54296.0 in 2020, then surged by 42.3% to $77265.0 in 2021, then dropped by 4.55% to $73750.0 in 2022.
• The last three Research & Development figures came in at $73750.0 (Q1 2022), $77265.0 (Q4 2021), and $72266.0 (Q3 2021), per Business Quant data.